The FDA has approved Ajovy (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children ages 6 to 17 who weigh at least 45 kg, making it the first migraine-prevention injection cleared for such young patients. The decision opens an injectable option for school-age children whose choices had largely been limited to oral drugs or off-label use. It also draws a firm line at 45 kg, leaving lighter children outside the new indication for now.
Why the new Ajovy pediatric approval matters now
The FDA decision gives clinicians a formally evaluated preventive shot for migraine in children as young as 6 years who meet the 45 kg weight requirement, according to the agency’s description of Ajovy’s expanded indication for “Children Ages 6 Years and Older Who Weigh 45 kg or More” on FDA. That weight-linked age bracket is central to who can receive the drug under the label and who cannot.
Official prescribing information on DailyMed states that Ajovy is indicated for preventive treatment of episodic migraine in pediatric patients 6 to 17 years old who weigh 45 kg or more. The same label notes that pediatric efficacy was evaluated in “Study 3,” which underpins the dosing and safety language for this age group.
The approval sits on a detailed clinical evaluation of a pediatric supplement, identified as sBLA 761089, which covers Ajovy for episodic migraine in patients 6 to 17 years who weigh at least 45 kg, according to the FDA’s clinical review of that application. That review describes how regulators assessed trial endpoints and adverse events before recommending the final indication tied to the 45 kg cutoff.
The central question is why the line is drawn at 45 kg. The FDA’s Office of Clinical Pharmacology concluded that the 45 kg threshold was appropriate for the pediatric indication, according to its pharmacology review of fremanezumab for this expansion. That review explains that the agency used exposure and pharmacokinetic comparisons to adult dosing to justify limiting the label to children whose body weight yields drug levels similar to adults at approved doses.
That logic supports the hypothesis that 45 kg functions more as a pharmacokinetic bridge than as a hard clinical boundary for whether the drug can help younger or smaller children. The pediatric trial that generated the key data stratified dosing by body weight below and above 45 kg, according to the peer-reviewed description of the study in the New England Journal of Medicine, which means the trial did collect data in lighter children even though the final label does not yet cover them.
The evidence behind the first migraine-prevention shot for young children
The core efficacy evidence comes from a randomized, placebo-controlled trial of fremanezumab in participants 6 to 17 years old with episodic migraine, registered as NCT04458857 on ClinicalTrials.gov and described in detail in a peer-reviewed article in the New England Journal of Medicine. That report notes that dosing in the pediatric study was stratified by body weight, with one group under 45 kg and another at or above 45 kg, aligning with the eventual regulatory threshold.
The same New England Journal of Medicine article identifies the trial as a placebo-controlled study that evaluated fremanezumab’s preventive effect on episodic migraine in this pediatric population. It provides evidence on migraine frequency, safety outcomes and how children and adolescents responded compared with placebo, forming the scientific backbone for the FDA’s evaluation.
Ajovy’s official label on DailyMed states that pediatric efficacy for Ajovy was evaluated in “Study 3,” which corresponds to the pediatric randomized trial and is the basis for the indication in patients 6 to 17 years who weigh at least 45 kg. The label connects Study 3 directly to the decision to approve Ajovy for episodic migraine prevention in that defined age and weight group.
The FDA clinical review for sBLA 761089 describes how the agency interpreted the Study 3 data for children 6 to 17 years weighing 45 kg or more. According to that evaluation, regulators considered reductions in migraine frequency and the pattern of adverse events when determining that the benefit-risk profile was acceptable for this subgroup.
Alongside the clinical review, the FDA Office of Clinical Pharmacology produced a separate analysis that “supports the ≥45 kg threshold for the Ajovy pediatric indication,” according to the pharmacology review document. That analysis explains how measured or modeled drug exposures in children at or above 45 kg align with adult exposures at approved doses, which were already supported by adult safety data.
The FDA’s annual report “Advancing Health Through Innovation: New Drug Therapy Approvals 2025” lists Ajovy’s pediatric episodic migraine approval for ages 6 to 17 at or above 45 kg as one of the year’s notable decisions. That report places the Ajovy expansion alongside other pediatric approvals and confirms that the 45 kg wording is part of the agency’s own summary of the decision.
Collectively, these documents show a consistent chain: Study 3 and trial NCT04458857 provide the primary clinical evidence in children, the clinical review sBLA 761089 interprets those data for patients 6 to 17 years who weigh at least 45 kg, and the Office of Clinical Pharmacology review ties the same 45 kg threshold to pharmacokinetic reasoning. The final label on DailyMed then codifies that evidence into a clear indication and dosing instructions for clinicians.
What remains unresolved after the Ajovy pediatric decision
The most immediate gap is what happens to children under 45 kg, even when they are within the 6 to 17 age range covered by the trial. The New England Journal of Medicine trial report states that dosing was stratified into body weight groups below and above 45 kg, meaning younger or smaller children were enrolled and received study drug or placebo, yet the approved indication on DailyMed only applies to those at or above 45 kg.
The FDA Office of Clinical Pharmacology review explains that the 45 kg cutoff is supported by pharmacokinetic considerations, aligning pediatric exposures with adult data. That supports the hypothesis that the threshold is primarily about matching drug levels rather than showing that children under 45 kg do not benefit. However, the available FDA documents do not present a separate efficacy conclusion for the under-45 kg group, leaving that question open based on the sources provided.
Another limitation is duration. The clinical review for sBLA 761089 focuses on the trial period that formed the basis for approval in 6 to 17 year olds weighing at least 45 kg. The documents available in the reporting block do not describe longer-term safety or immunogenicity results beyond that evaluation window, so any assessment of multi-year use in children remains outside the verified record here.
Real-world experience is also largely absent from the current evidence set. The prescribing information on DailyMed summarizes adverse reactions observed in controlled settings, but it does not include postmarketing adherence patterns or long-term outcome data in routine pediatric practice. The FDA’s safety and recalls page that references Ajovy prescribing information provides a pathway for reporting issues but does not yet reflect broad pediatric experience with this new indication.
For families and clinicians, the practical consequence is a new option with clear boundaries. Children 6 to 17 who weigh at least 45 kg now have an FDA-reviewed injectable preventive therapy described in the Ajovy label and supported by Study 3 and NCT04458857. Those below 45 kg, even if they experience frequent migraines, remain outside the approved dosing framework based on the current FDA pharmacology and clinical reviews.
The next development to watch is whether future analyses of the under-45 kg cohort from NCT04458857, or new weight-stratified studies, prompt the FDA to revisit the threshold that its Office of Clinical Pharmacology currently supports. Until then, the first migraine-prevention shot cleared for children as young as six arrives with a firm 45 kg dividing line that shapes who can receive it under the label and who must still rely on other approaches.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
